

# John Kenneth Marshall

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2645412/publications.pdf>

Version: 2024-02-01

211  
papers

14,101  
citations

28190

55  
h-index

22102

113  
g-index

215  
all docs

215  
docs citations

215  
times ranked

13695  
citing authors

#	ARTICLE	IF	CITATIONS
1	Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. <i>Gastroenterology</i> , 2015, 149, 102-109.e6.	0.6	1,161
2	ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 4-22.	0.6	741
3	The Toronto Consensus for the Treatment of <i>Helicobacter pylori</i> Infection in Adults. <i>Gastroenterology</i> , 2016, 151, 51-69.e14.	0.6	671
4	Systematic Review of the Risk of Enteric Infection in Patients Taking Acid Suppression. <i>American Journal of Gastroenterology</i> , 2007, 102, 2047-2056.	0.2	538
5	ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 155-168.	0.6	478
6	Antibiotic Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 661-673.	0.2	469
7	Consensus Recommendations for Managing Patients with Nonvariceal Upper Gastrointestinal Bleeding. <i>Annals of Internal Medicine</i> , 2003, 139, 843.	2.0	458
8	The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. <i>Gastroenterology</i> , 2016, 150, 734-757.e1.	0.6	373
9	Incidence and Epidemiology of Irritable Bowel Syndrome After a Large Waterborne Outbreak of Bacterial Dysentery. <i>Gastroenterology</i> , 2006, 131, 445-450.	0.6	338
10	Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus. <i>Gastroenterology</i> , 2015, 148, 1035-1058.e3.	0.6	323
11	Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group. <i>Annals of Internal Medicine</i> , 2019, 171, 805.	2.0	310
12	Consensus Statements on the Risk, Prevention, and Treatment of Venous Thromboembolism in Inflammatory Bowel Disease: Canadian Association of Gastroenterology. <i>Gastroenterology</i> , 2014, 146, 835-848.e6.	0.6	277
13	Clinical practice guideline: management of acute pancreatitis. <i>Canadian Journal of Surgery</i> , 2016, 59, 128-140.	0.5	269
14	Glucocorticosteroid Therapy in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 590-599.	0.2	266
15	Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk. <i>Gastroenterology</i> , 2000, 119, 1740-1744.	0.6	253
16	Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: Prevalence and impact on health. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 38-46.	0.9	249
17	Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 601-616.	0.2	231
18	Postinfectious Irritable Bowel Syndrome After a Food-Borne Outbreak of Acute Gastroenteritis Attributed to a Viral Pathogen. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 457-460.	2.4	224

#	ARTICLE	IF	CITATIONS
19	Genetic Risk Factors for Post-Infectious Irritable Bowel Syndrome Following a Waterborne Outbreak of Gastroenteritis. <i>Gastroenterology</i> , 2010, 138, 1502-1513.	0.6	208
20	Canadian Consensus Conference on the Management of Gastroesophageal Reflux Disease in Adults â€“ Update 2004. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2005, 19, 15-35.	1.8	204
21	Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. <i>Gut</i> , 2010, 59, 605-611.	6.1	189
22	The Probiotic VSL#3 Has Anti-inflammatory Effects and Could Reduce Endoscopic Recurrence After Surgery for Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 928-935.e2.	2.4	181
23	Minimizing postcolonoscopy abdominal pain by using CO2 insufflation: A prospective, randomized, double blind, controlled trial evaluating a new commercially available CO2 delivery system. <i>Gastrointestinal Endoscopy</i> , 2002, 56, 190-194.	0.5	177
24	Efficacy of 5-Aminosalicylates in Crohn's Disease: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 617-629.	0.2	170
25	Validation of international algorithms to identify adults with inflammatory bowel disease in health administrative data from Ontario, Canada. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 887-896.	2.4	157
26	Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids. <i>American Journal of Gastroenterology</i> , 2016, 111, 477-491.	0.2	151
27	Post-infectious irritable bowel syndrome. <i>World Journal of Gastroenterology</i> , 2009, 15, 3591.	1.4	149
28	Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis. <i>Intensive Care Medicine</i> , 2021, 47, 521-537.	3.9	148
29	Effect of a multifaceted educational intervention for anti-infectious measures on sepsis mortality: a cluster randomized trial. <i>Intensive Care Medicine</i> , 2017, 43, 1602-1612.	3.9	143
30	Treatment of Hospitalized Adult Patients With Severe Ulcerative Colitis: Toronto Consensus Statements. <i>American Journal of Gastroenterology</i> , 2012, 107, 179-194.	0.2	142
31	Association of ultra-processed food intake with risk of inflammatory bowel disease: prospective cohort study. <i>BMJ, The</i> , 2021, 374, n1554.	3.0	136
32	Measuring Patient Preferences for Colorectal Cancer Screening Using a Choice-Format Survey. <i>Value in Health</i> , 2007, 10, 415-430.	0.1	128
33	Fecal Transplant via Retention Enema for Refractory or Recurrent <i>Clostridium difficile</i> Infection. <i>Archives of Internal Medicine</i> , 2012, 172, 191.	4.3	117
34	Cellular Immunotherapy for Septic Shock. A Phase I Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 337-347.	2.5	115
35	Putting Rectal 5-Aminosalicylic Acid in Its Place: The Role in Distal Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2000, 95, 1628-1636.	0.2	111
36	Impact of including or excluding both-armed zero-event studies on using standard meta-analysis methods for rare event outcome: a simulation study. <i>BMJ Open</i> , 2016, 6, e010983.	0.8	110

#	ARTICLE	IF	CITATIONS
37	A Randomized Controlled Trial of Laparoscopic Nissen Fundoplication Versus Proton Pump Inhibitors for Treatment of Patients With Chronic Gastroesophageal Reflux Disease: One-Year Follow-Up. <i>Surgical Innovation</i> , 2006, 13, 238-249.	0.4	94
38	An Outbreak of Acute Bacterial Gastroenteritis Is Associated With an Increased Incidence of Irritable Bowel Syndrome in Children. <i>American Journal of Gastroenterology</i> , 2010, 105, 933-939.	0.2	93
39	Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 50-74.	0.6	87
40	Epidemiological Aspects of Irritable Bowel Syndrome in Europe and North America. <i>Digestion</i> , 2001, 64, 200-204.	1.2	86
41	Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. <i>The Cochrane Library</i> , 2010, , CD004115.	1.5	85
42	A randomized controlled trial of laparoscopic Nissen fundoplication versus proton pump inhibitors for the treatment of patients with chronic gastroesophageal reflux disease (GERD): 3-year outcomes. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2011, 25, 2547-2554.	1.3	83
43	CD23-Mediated IgE Transport Across Human Intestinal Epithelium: Inhibition by Blocking Sites of Translation or Binding. <i>Gastroenterology</i> , 2005, 129, 928-940.	0.6	75
44	Prevalence of Uninvestigated Dyspepsia 8 Years After a Large Waterborne Outbreak of Bacterial Dysentery: A Cohort Study. <i>Gastroenterology</i> , 2010, 138, 1727-1736.	0.6	75
45	How do physician assessments of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a stated-choice survey. <i>Health Economics (United Kingdom)</i> , 2009, 18, 1420-1439.	0.8	74
46	Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1-13.	0.9	73
47	Development of the IBD Disk. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 333-340.	0.9	72
48	Anti-TNF Therapies Are Safe During Pregnancy in Women with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1862-1869.	0.9	69
49	Clinical Practice Guideline on Screening for Colorectal Cancer in Individuals With a Family History of Nonhereditary Colorectal Cancer or Adenoma: The Canadian Association of Gastroenterology Banff Consensus. <i>Gastroenterology</i> , 2018, 155, 1325-1347.e3.	0.6	69
50	Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: An indirect treatment comparison meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 571-581.	0.6	66
51	Impact of High-Dose Vitamin D3 Supplementation in Patients with Crohn's Disease in Remission: A Pilot Randomized Double-Blind Controlled Study. <i>Digestive Diseases and Sciences</i> , 2017, 62, 448-455.	1.1	65
52	Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 271-280.	1.9	65
53	Systematic Review. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1683-1694.	0.9	64
54	Sepsis: frontiers in supportive care, organisation and research. <i>Intensive Care Medicine</i> , 2017, 43, 496-508.	3.9	62

#	ARTICLE	IF	CITATIONS
55	The Incidence of Irritable Bowel Syndrome Among Community Subjects With Previous Acute Enteric Infection. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1026-1032.	1.1	58
56	Management of inflammatory bowel disease with vitamin D: Beyond bone health. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 397-404.	0.6	54
57	Development and Validation of a Risk Score for Post-Infectious Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2009, 104, 2267-2274.	0.2	53
58	Are Patients with Inflammatory Bowel Disease at Increased Risk of Coronary Artery Disease?. <i>American Journal of Medicine</i> , 2012, 125, 956-962.	0.6	49
59	Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease. <i>Gastroenterology</i> , 2019, 157, 320-348.	0.6	49
60	14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by <i>Helicobacter pylori</i> status. <i>Journal of Rheumatology</i> , 2002, 29, 1965-74.	1.0	44
61	Incremental Cost-Effectiveness Analysis Comparing Rofecoxib with Nonselective NSAIDs in Osteoarthritis. <i>Pharmacoeconomics</i> , 2001, 19, 1039-1049.	1.7	41
62	Hormonal therapy for bleeding gastrointestinal mucosal vascular abnormalities: a promising alternative. <i>European Journal of Gastroenterology and Hepatology</i> , 1997, 9, 521-525.	0.8	40
63	Postinfectious IBS: Defining its clinical features and prognosis using an internet-based survey. <i>United European Gastroenterology Journal</i> , 2018, 6, 1245-1253.	1.6	40
64	Canadian Association of Gastroenterology Clinical Practice Guideline on the Management of Bile Acid Diarrhea. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 24-41.e1.	2.4	40
65	Resource Utilization for Acute Lower Gastrointestinal Hemorrhage: The Ontario GI Bleed Study. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2002, 16, 677-682.	1.8	38
66	Management of Patients With Nonvariceal Upper Gastrointestinal Bleeding. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 234-239.	2.4	36
67	The importance of airway and lung microbiome in the critically ill. <i>Critical Care</i> , 2020, 24, 537.	2.5	36
68	Canadian Association of Gastroenterology Position Statement: Fecal Microbiota Transplant Therapy. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2014, 28, 66-68.	0.8	35
69	Omeprazole for Refractory Gastroesophageal Reflux Disease during Pregnancy and Lactation. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 1998, 12, 225-227.	1.8	34
70	A gradient of acute gastroenteritis was characterized, to assess risk of long-term health sequelae after drinking bacterial-contaminated water. <i>Journal of Clinical Epidemiology</i> , 2006, 59, 421-428.	2.4	34
71	Prediction of Resource Utilization and Case Cost for Acute Nonvariceal Upper Gastrointestinal Hemorrhage at A Canadian Community Hospital. <i>American Journal of Gastroenterology</i> , 1999, 94, 1841-1846.	0.2	33
72	Resource utilization during pediatric to adult transfer of care in IBD. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e55-e60.	0.6	33

#	ARTICLE	IF	CITATIONS
73	The gastrointestinal tolerability and safety of oral bisphosphonates. Expert Opinion on Drug Safety, 2002, 1, 71-78.	1.0	32
74	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 1680-1713.	2.4	32
75	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. Journal of the Canadian Association of Gastroenterology, 2019, 2, e1-e34.	0.1	32
76	Long-term Health Sequelae Following E.coli and Campylobacter Contamination of Municipal Water. Canadian Journal of Public Health, 2005, 96, 125-130.	1.1	30
77	Cost-Utility of Laparoscopic Nissen Fundoplication versus Proton Pump Inhibitors for Chronic and Controlled Gastroesophageal Reflux Disease: A 3-Year Prospective Randomized Controlled Trial and Economic Evaluation. Value in Health, 2011, 14, 263-273.	0.1	30
78	Prevalence and patient awareness of inflammatory bowel disease in Kazakhstan: a cross-sectional study. Intestinal Research, 2020, 18, 430-437.	1.0	30
79	The Impact of Reference Pricing of Nonsteroidal Anti-Inflammatory Agents on the Use and Costs of Analgesic Drugs. Health Services Research, 2005, 40, 1297-1317.	1.0	29
80	Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF- $\alpha$ drugs for refractory Crohn's disease. Journal of Crohn's and Colitis, 2012, 6, 77-85.	0.6	29
81	Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. The Cochrane Library, 2012, 11, CD004118.	1.5	29
82	Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease. American Journal of Gastroenterology, 2022, 117, 1106-1117.	0.2	28
83	Ketotifen Treatment of Active Colitis in Patients with 5-Aminosalicylate Intolerance. Canadian Journal of Gastroenterology & Hepatology, 1998, 12, 273-275.	1.8	27
84	Fecal Occult Blood Testing as a Diagnostic Test in Symptomatic Patients is not Useful: A Retrospective Chart Review. Canadian Journal of Gastroenterology and Hepatology, 2014, 28, 421-426.	0.8	27
85	Test-and-Treat Strategies for Helicobacter pylori in Uninvestigated Dyspepsia: A Canadian Economic Analysis. Canadian Journal of Gastroenterology & Hepatology, 2000, 14, 379-388.	1.8	26
86	Cost-Effectiveness and Cost-Utility of Long-Term Management Strategies for Heartburn. Value in Health, 2002, 5, 312-328.	0.1	26
87	Post-infectious irritable bowel syndrome following water contamination. Kidney International, 2009, 75, S42-S43.	2.6	26
88	IgG4-Related Sclerosing Disease: A Novel Mimic of Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2010, 55, 3047-3051.	1.1	26
89	Mesalamine (5-ASA) for the prevention of recurrent diverticulitis. The Cochrane Library, 2017, 2017, CD009839.	1.5	26
90	Active Margins, Plexitis, and Granulomas Increase Postoperative Crohn's Disease Recurrence: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2021, 19, 451-462.	2.4	26

#	ARTICLE	IF	CITATIONS
91	Acute Cardiac Injury in Coronavirus Disease 2019 and Other Viral Infections—A Systematic Review and Meta-Analysis. <i>Critical Care Medicine</i> , 2021, 49, 1558-1566.	0.4	26
92	Canadian Association of Gastroenterology Clinical Practice Guidelines: The Use of Infliximab in Crohn's Disease. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2004, 18, 503-508.	1.8	25
93	Adherence to Guidelines for Surveillance Colonoscopy in Patients with Ulcerative Colitis at a Canadian Quaternary Care Hospital. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2009, 23, 613-617.	1.8	25
94	Successful Therapy of Refractory Erythema Nodosum Associated with Crohn's Disease Using Potassium Iodide. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 1997, 11, 501-502.	1.8	24
95	Prospective Comparison of Small Bowel Meal with Pneumocolon versus Ileo-Colonoscopy for the Diagnosis of Ileal Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2004, 99, 1321-1329.	0.2	24
96	Economic Analysis of Home vs Hospital-Based Parenteral Nutrition in Ontario, Canada. <i>Journal of Parenteral and Enteral Nutrition</i> , 2005, 29, 266-269.	1.3	24
97	Role of probiotics in management of diverticular disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1827-1830.	1.4	24
98	Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial. <i>American Journal of Gastroenterology</i> , 2020, 115, 1236-1245.	0.2	23
99	Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia. <i>Cmaj</i> , 2002, 166, 1655-62.	0.9	23
100	An empirical comparison of methods for analyzing correlated data from a discrete choice survey to elicit patient preference for colorectal cancer screening. <i>BMC Medical Research Methodology</i> , 2012, 12, 15.	1.4	22
101	Treatment Algorithm for Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome Derived from a Canadian National Survey and Needs Assessment on Choices of Therapeutic Agents. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2017, 2017, 1-11.	0.8	22
102	Immune Stimulation Using a Gut Microbe-Based Immunotherapy Reduces Disease Pathology and Improves Barrier Function in Ulcerative Colitis. <i>Frontiers in Immunology</i> , 2018, 9, 2211.	2.2	22
103	Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary. <i>Journal of Rheumatology</i> , 2019, 46, 751-754.	1.0	22
104	Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1579-1587.e2.	2.4	22
105	Analysis of Genetic Association of Intestinal Permeability in Healthy First-degree Relatives of Patients with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1796-1804.	0.9	21
106	The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies. <i>United European Gastroenterology Journal</i> , 2021, 9, 581-589.	1.6	21
107	Early Change in Epithelial Neutrophilic Infiltrate Predicts Long-Term Response to Biologics in Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1095-1104.e9.	2.4	21
108	An Audit of Influenza Vaccination Status in Adults with Inflammatory Bowel Disease. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2012, 26, 593-596.	1.8	20

#	ARTICLE	IF	CITATIONS
109	Practice Variation in Spontaneous Breathing Trial Performance and Reporting. Canadian Respiratory Journal, 2016, 2016, 1-10.	0.8	18
110	Predicting endoscopic remission in Crohn's disease by the modified multiplier SES-CD (MM-SES-CD). Gut, 2022, 71, 1078-1087.	6.1	18
111	929c A randomized, placebo controlled trial of fecal microbiota therapy in active ulcerative colitis.. Gastroenterology, 2014, 146, S-159.	0.6	17
112	Managing Inflammatory Bowel Disease During COVID-19: Summary of Recommendations from Gastrointestinal Societies. Clinical Gastroenterology and Hepatology, 2020, 18, 2143-2146.	2.4	17
113	Terminal Ileal Imaging With Ileoscopy Versus Small-Bowel Meal With Pneumocolon. Journal of Clinical Gastroenterology, 1998, 27, 217-222.	1.1	17
114	Probiotics: Prevention of Severe Pneumonia and Endotracheal Colonization Trial's PROSPECT: protocol for a feasibility randomized pilot trial. Pilot and Feasibility Studies, 2015, 1, 19.	0.5	16
115	Impact of the Adalimumab Patient Support Program's Care Coach Calls on Persistence and Adherence in Canada: An Observational Retrospective Cohort Study. Clinical Therapeutics, 2018, 40, 415-429.e6.	1.1	16
116	Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease. Journal of the Canadian Association of Gastroenterology, 2019, 2, e35-e63.	0.1	16
117	Canadian Association of Gastroenterology Clinical Practice Guideline on the Management of Bile Acid Diarrhea. Journal of the Canadian Association of Gastroenterology, 2020, 3, e10-e27.	0.1	16
118	Clinical Management of the Microbiome in Irritable Bowel Syndrome. Journal of the Canadian Association of Gastroenterology, 2021, 4, 36-43.	0.1	16
119	Week 6 Calprotectin Best Predicts Likelihood of Long-term Endoscopic Healing in Crohn's Disease: A Post-hoc Analysis of the UNITI/IM-UNITI Trials. Journal of Crohn's and Colitis, 2021, 15, 462-470.	0.6	16
120	Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis/Meta-regression Adjusted for Confounding Factors. CJC Open, 2021, 3, 965-975.	0.7	15
121	Patient outcomes after anti TNF- $\alpha$ drugs for Crohn's disease. Expert Review of Pharmacoeconomics and Outcomes Research, 2010, 10, 163-175.	0.7	14
122	Understanding the Global Epidemiology of Pediatric Critical Illness. Pediatric Critical Care Medicine, 2014, 15, 660-666.	0.2	14
123	Impact of Digital Health Monitoring in the Management of Inflammatory Bowel Disease. Journal of Medical Systems, 2021, 45, 23.	2.2	14
124	Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD) - Part 2: Inactivated Vaccines. Gastroenterology, 2021, 161, 681-700.	0.6	14
125	Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission. Alimentary Pharmacology and Therapeutics, 2020, 52, 1676-1682.	1.9	14
126	Photodynamic Therapy for Barrett's Esophagus with High-Grade Dysplasia: A Cost-Effectiveness Analysis. Canadian Journal of Gastroenterology & Hepatology, 2007, 21, 217-222.	1.8	13



#	ARTICLE	IF	CITATIONS
127	Demographic Predictors of Resource Utilization for Bleeding Peptic Ulcer Disease: The Ontario GI Bleed Study. <i>Journal of Clinical Gastroenterology</i> , 1999, 29, 165-170.	1.1	13
128	Randomized Active and Placebo-Controlled Endoscopy Study of a Novel Protected Formulation of Oral Alendronate. <i>Digestive Diseases and Sciences</i> , 2006, 51, 864-868.	1.1	12
129	Should Albumin Be Used in All Patients with Spontaneous Bacterial Peritonitis?. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2011, 25, 373-376.	1.8	12
130	Systematic review and meta-analysis: Safety of vedolizumab during pregnancy in patients with inflammatory bowel disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2640-2648.	1.4	12
131	Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1588-1597.e3.	2.4	12
132	Should My Patient with Inflammatory Bowel Disease on Immunosuppressive Therapy be Vaccinated against Influenza Virus?. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2010, 24, 121-125.	1.8	11
133	A Comparison of the Prevalence of Anxiety and Depression Between Uncomplicated and Complex IBD Patient Groups. <i>Gastroenterology Nursing</i> , 2018, 41, 427-435.	0.2	11
134	Body Mass Index Does Not Impact Clinical Efficacy of Ustekinumab in Crohn's Disease: A Post Hoc Analysis of the IM-UNITI Trial. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 848-854.	0.9	11
135	Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD) – Part 1: Live Vaccines. <i>Gastroenterology</i> , 2021, 161, 669-680.e0.	0.6	11
136	Lymphocytic and collagenous colitis: Medical management. <i>Current Treatment Options in Gastroenterology</i> , 1999, 2, 127-133.	0.3	10
137	Review and Clinical Perspectives for the Use of Infliximab in Ulcerative Colitis. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2008, 22, 261-272.	1.8	10
138	Canadian Association of Gastroenterology Position Statement Regarding the Use of Thiopurines for the Treatment of Inflammatory Bowel Disease. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2014, 28, 371-372.	0.8	10
139	Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018, 1, 141-154.	0.1	10
140	Does a High-inflammatory Diet Increase the Risk of Inflammatory Bowel Disease? Results From the Prospective Urban Rural Epidemiology (PURE) Study: A Prospective Cohort Study. <i>Gastroenterology</i> , 2021, 161, 1333-1335.e1.	0.6	10
141	Marked Elevation of Serum Transaminases May Be Associated With Ovarian Hyperstimulation Syndrome. <i>American Journal of Gastroenterology</i> , 1999, 94, 3373.	0.2	9
142	A Critical Approach to Clinical Practice Guidelines. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2000, 14, 505-509.	1.8	9
143	Assessing the Educational Needs of Canadian Gastroenterologists and Gastroenterology Nurses: Challenges to Optimal Care in Crohn's Disease. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2009, 23, 805-810.	1.8	9
144	Safety of Esophagogastroduodenoscopy within 30 Days of Myocardial Infarction: A Retrospective Cohort Study from a Canadian Tertiary Centre. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2012, 26, 151-154.	1.8	9

#	ARTICLE	IF	CITATIONS
145	Pathogens and antimicrobial susceptibility profiles in critically ill patients with bloodstream infections: a descriptive study. <i>CMAJ Open</i> , 2016, 4, E569-E577.	1.1	9
146	End of Induction Patient-reported Outcomes Predict Clinical Remission but Not Endoscopic Remission in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1114-1119.	0.6	9
147	Colorectal cancer screening for patients with a family history of colorectal cancer or adenomas. <i>Canadian Family Physician</i> , 2019, 65, 784-789.	0.1	9
148	Use and misuse of cost-effectiveness terminology in the gastroenterology literature: a systematic review. <i>American Journal of Gastroenterology</i> , 2002, 97, 172-179.	0.2	8
149	Identifying Needs in Young Adults With Inflammatory Bowel Disease. <i>Gastroenterology Nursing</i> , 2018, 41, 19-28.	0.2	8
150	A Cost-Utility Analysis of Switching from Reference to Biosimilar Infliximab Compared to Maintaining Reference Infliximab in Adult Patients with Crohn's Disease. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, 48-48.	0.1	8
151	Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD) – Part 2: Inactivated Vaccines. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, e72-e91.	0.1	8
152	Canadian Consensus Statements on the Transition of Adolescents and Young Adults with Inflammatory Bowel Disease from Pediatric to Adult Care: A Collaborative Initiative Between the Canadian IBD Transition Network and Crohn's and Colitis Canada. <i>Journal of the Canadian Association of Gastroenterology</i> , 2022, 5, 105-115.	0.1	8
153	Does acetylsalicylic acid or warfarin affect the accuracy of fecal occult blood tests?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 931-936.	1.4	7
154	FLUID trial: a protocol for a hospital-wide open-label cluster crossover pragmatic comparative effectiveness randomised pilot trial. <i>BMJ Open</i> , 2018, 8, e022780.	0.8	7
155	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Health Care Delivery During the Pandemic and the Future Model of Inflammatory Bowel Disease Care. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, S61-S67.	0.1	7
156	Patients' Experiences and Challenges in Living with Inflammatory Bowel Disease: A Qualitative Approach. <i>Clinical and Experimental Gastroenterology</i> , 2021, Volume 14, 123-131.	1.0	7
157	Clinical trials for coronavirus disease 2019: What is being evaluated and what is not. <i>Annals of Thoracic Medicine</i> , 2020, 15, 49.	0.7	7
158	Novel Microbial-Based Immunotherapy Approach for Crohn's Disease. <i>Frontiers in Medicine</i> , 2019, 6, 170.	1.2	6
159	Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD) – Part 1: Live Vaccines. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, e59-e71.	0.1	6
160	Categorising Endoscopic Severity of Crohn's Disease Using the Modified Multiplier SES-CD [MM-SES-CD]. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1011-1019.	0.6	6
161	Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn's Disease With a Loss of Response. <i>Journal of the Canadian Association of Gastroenterology</i> , 2022, 5, 208-213.	0.1	6
162	Bell's palsy in a patient receiving adalimumab for Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e115.	0.6	5

#	ARTICLE	IF	CITATIONS
163	Bayesian approach to the assessment of the population-specific risk of inhibitors in hemophilia A patients: a case study. <i>Journal of Blood Medicine</i> , 2016, Volume 7, 239-253.	0.7	5
164	Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies—Executive Summary. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, 149-152.	0.1	5
165	Effect of age of transfused red blood cells on neurologic outcome following traumatic brain injury (ABLE-tbi Study): a nested study of the Age of Blood Evaluation (ABLE) trial. <i>Canadian Journal of Anaesthesia</i> , 2019, 66, 696-705.	0.7	5
166	OUP accepted manuscript. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, S1-S9.	0.1	5
167	Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1555-1564.	0.9	5
168	The Performance of the Rutgeerts Score, SES-CD, and MM-SES-CD for Prediction of Postoperative Clinical Recurrence in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 716-725.	0.9	5
169	Are there epidemiological differences between crohn's disease and ulcerative colitis?. <i>Inflammatory Bowel Diseases</i> , 2008, 14, S1.	0.9	4
170	Review: azathioprine, infliximab, certolizumab, and adalimumab are effective for maintaining remission in Crohn's disease. <i>Evidence-Based Medicine</i> , 2008, 13, 115-115.	0.6	4
171	Reduction in Anxiety and Depression Scores Associated with Improvement in Quality of Life in Patients with Inflammatory Bowel Disease. <i>Journal of the Canadian Association of Gastroenterology</i> , 2022, 5, 12-17.	0.1	4
172	Resolution of dominant patient-reported outcome at end of induction predicts clinical and endoscopic remission in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1151-1159.	1.9	4
173	Reporting ileocolonoscopy in Inflammatory Bowel Disease. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2006, 20, 399-400.	1.8	3
174	842 Genetic Risk Factors for Post-Infectious IBS in the Walkerton Outbreak of Waterborne Gastroenteritis. <i>Gastroenterology</i> , 2008, 134, A-122.	0.6	3
175	New Applications for Traditional Drugs in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2948-2957.	0.9	3
176	Patterns and predictors of long-term retention of inflammatory bowel or rheumatoid disease patients on innovator infliximab: an analysis of a Canadian prescriptions claims database. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 1805-1814.	0.8	3
177	Canada's Study of Adherence Outcomes in Patients Receiving Adalimumab: 3-year Results From the COMPANION Study. <i>Clinical Therapeutics</i> , 2018, 40, 1024-1032.	1.1	3
178	Anxiety, Depression and Quality of Life Improve After One Month and Three Months of Home Parenteral Nutrition: A Pilot Study in a Canadian Population. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, 178-185.	0.1	3
179	Fecal Microbiota Transplantation for the Treatment of Ulcerative Colitis: A Qualitative Assessment of Patient Perceptions and Experiences. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, e120-e129.	0.1	3
180	Periodic Colonoscopies Are Associated with Improved Survival and Prognosis of Colorectal Cancer in Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 1850-1857.	1.1	3

#	ARTICLE	IF	CITATIONS
181	Response to "Potentially Flawed Interpretation of Data by Andriulli et al.". American Journal of Gastroenterology, 2005, 100, 2133-2133.	0.2	2
182	The Burden of Celiac Disease in Canada: More Work Needed to Lighten the Load. Canadian Journal of Gastroenterology & Hepatology, 2013, 27, 448-448.	1.8	2
183	Reply. Gastroenterology, 2017, 152, 303-304.	0.6	2
184	Impact of Adalimumab Patient Support Program's Care Coach Calls on Clinical Outcomes in Patients with Crohn's Disease in Canada: An Observational Retrospective Cohort Study. Journal of the Canadian Association of Gastroenterology, 2018, 1, 191-198.	0.1	2
185	Higher adalimumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2019, 54, 712-717.	0.6	2
186	Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 997-998.	1.9	2
187	Higher vedolizumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2020, 55, 800-805.	0.6	2
188	Crohn's and Colitis Canada's 2021 Impact of COVID-19 & Inflammatory Bowel Disease in Canada: A Knowledge Translation Strategy. Journal of the Canadian Association of Gastroenterology, 2021, 4, S10-S19.	0.1	2
189	Stability of diagnostic rate in a cohort of 38,813 colorectal polyp specimens and implications for histomorphology and statistical process control. Scientific Reports, 2021, 11, 16942.	1.6	2
190	Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for 1-year Endoscopic Remission in Moderate to Severe Crohn's Disease. Journal of Crohn's and Colitis, 2022, 16, 616-624.	0.6	2
191	Ozanimod for the Treatment of Ulcerative Colitis. Gastroenterology, 2022, 162, 2104-2106.	0.6	2
192	Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada. PharmacoEconomics - Open, 2022, 6, 519-537.	0.9	2
193	Funding the New Biologics - CCOHTA Report on the Cost Effectiveness of Infliximab for Crohn's Disease: Pearls and Pitfalls. Canadian Journal of Gastroenterology & Hepatology, 2002, 16, 877-879.	1.8	1
194	Finding Inflammatory Bowel Disease Genes Will Not Lead to a Cure. Canadian Journal of Gastroenterology & Hepatology, 2006, 20, 643-644.	1.8	1
195	Myocardial Infarction, Peptic Ulcer and Acetylsalicylic Acid: Of Good and Evil. Canadian Journal of Gastroenterology & Hepatology, 2009, 23, 618-618.	1.8	1
196	Conventional Medical Management of Ulcerative Colitis: Sulfasalazine and 5-Aminosalicylates. , 2012, , 453-466.		1
197	The Origins of Irritable Bowel Syndrome: Experience of a Lifetime. Gastroenterology, 2014, 147, 18-20.	0.6	1
198	Sulfasalazine and 5-Aminosalicylates for Ulcerative Colitis. , 2017, , 389-397.		1

#	ARTICLE	IF	CITATIONS
199	Multidisciplinary damage control management of life-threatening carotid blowout syndrome. Trauma Surgery and Acute Care Open, 2018, 3, e000166.	0.8	1
200	Counselling patients for return to work on immunosuppression: practices of Canadian specialists during the COVID-19 pandemic. Clinical and Experimental Rheumatology, 2021, 39, 874-878.	0.4	1
201	Editorial: is it not just <sc>PRO</sc> s, but the most important individual <sc>PRO</sc> , that really matters in Crohn's disease? Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 55, 1040-1041.	1.9	1
202	A Semiquantitative Stool Antigen Test for Helicobacter pylori. Journal of Clinical Gastroenterology, 2002, 35, 369-370.	1.1	0
203	Talk Is Cheap: The Impact of Consultation. Commentary on the Article. Canadian Journal of Gastroenterology & Hepatology, 2004, 18, 181-182.	1.8	0
204	The journey Continues. Canadian Journal of Gastroenterology and Hepatology, 2015, 29, 175-175.	0.8	0
205	Patients and Practice Guidelines: Keeping Eyes on the Horizon. Canadian Journal of Gastroenterology and Hepatology, 2015, 29, 290-290.	0.8	0
206	Fecal transplantation for recurrent or refractory Clostridium difficile diarrhea. The Cochrane Library, 0, , .	1.5	0
207	Journal of the Canadian Association of Gastroenterology. Journal of the Canadian Association of Gastroenterology, 2018, 1, 1-1.	0.1	0
208	In Barrett esophagus, high- vs low-dose esomeprazole improved clinical outcomes; aspirin vs no aspirin did not. Annals of Internal Medicine, 2018, 169, JC54.	2.0	0
209	Comparative effectiveness of higher adalimumab maintenance therapy versus standard dose in anti-tumor necrosis factor experienced Crohn's disease patients: A propensity score matched cohort analysis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2803-2812.	1.4	0
210	Reply. Clinical Gastroenterology and Hepatology, 2021, , .	2.4	0
211	Epithelial Neutrophilic Infiltrate: The Rising Star in Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2021, , .	2.4	0